Length 390 pages

Date published October 2008

Print copies are available upon request. Call 781-972-5444. 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Immunotherapies and Vaccines for Cancer and Infectious Diseases Table of Contents

 

Author: Lucy J. Sannes, PhD, MBA

Chapter 1
INTRODUCTION
1.1. The Immune System
1.2. Scope of This Report

Chapter 2
MAJOR CANCERS AND INFECTIOUS DISEASES TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO ENHANCE THE IMMUNE SYSTEM
2.1. Major Cancers Targeted by Immunotherapies and Vaccines
  Brain Cancer
  Breast Cancer
  Cervical Cancer
  Colorectal Cancer
  Leukemia
  Lung Cancer
       Non–Small-Cell Lung Cancer
       Small-Cell Lung Cancer
  Lymphoma (Non–Hodgkin’s Lymphoma)
  Melanoma
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Renal Cancer
2.2. Major Infectious Diseases Targeted by Emerging Immunotherapies and Vaccines
  Anthrax
  Campylobacter
  Cytomegalovirus
  Dengue
  Diphtheria
  Encephalitis
  Haemophilus influenzae Type b
  Hepatitis B Virus
  Hepatitis C Virus
  Herpes Simplex Virus
  Human Immunodeficiency Virus
  Human Papillomavirus
  Influenza
  Malaria
  Meningococcal Disease; Neisseria meningitidis
  Pertussis
  Pneumococcal Disease; Streptococcus pneumoniae
  Polio (Poliomyelitis)
  Respiratory Syncytial Virus
  Tetanus
  Tuberculosis
  West Nile Virus

Chapter 3
CURRENT PHARMACOLOGICAL OPTIONS FOR TREATMENT AND PREVENTION OF CANCER, AND IMMUNOTHERAPY/VACCINE OPTIONS FOR TREATMENT AND PREVENTION OF INFECTIOUS DISEASES
3.1. Current Pharmacological Options for Treatment and Prevention of Cancer
  Brain Cancer
  Breast Cancer
       Chemotherapy
       Hormone Therapy
       Targeted Therapy: HER2-Positive Cancers
       Targeted Therapy: VEGF and Angiogenesis
  Cervical Cancer
  Colorectal Cancer
       Chemotherapy
       Targeted Therapy: Monoclonal Antibodies
  Leukemia
       Pharmacological Therapies (Chemotherapy and Others)
       Bone Marrow Transplants and Peripheral Stem Cell Transplants
  Lung Cancer
       Chemotherapy (Non–Small-Cell Lung Cancer)
       Targeted Therapy: Kinase Inhibitors (Non–Small-Cell Lung Cancer)
       Targeted Therapy: Monoclonal Antibodies (Non–Small-Cell Lung Cancer)
       Photodynamic Therapy (Non–Small-Cell Lung Cancer)
       Chemotherapy (Small-Cell Lung Cancer)
  Lymphoma (Non–Hodgkin’s Lymphoma)
       Chemotherapy
       Monoclonal Antibodies
       Other Immune-Based Therapies
       Other Targeted Therapies: Histone Deacetylase Inhibitor
  Melanoma
        Interferon
        Interleukin-2
        Chemotherapy
  Ovarian Cancer
  Pancreatic Cancer
        Chemotherapy
        Targeted Therapy: Inhibition of EGFR Tyrosine Kinase
  Prostate Cancer
        Luteinizing Hormone–Releasing Hormone Agonists
        Antiandrogens
        Chemotherapy
  Renal Cancer
        Interferon
        Interleukin-2
        Targeted Therapy: Kinase Inhibitors
3.2. Current Infectious Disease Immunotherapies and Vaccines
  Passive Immunotherapy
  Immunotherapy for Treatment of Chronic Infections
  Infectious Disease Vaccines
3.3. Medical and Market Needs; R&D Challenges
  Cancer Immunotherapies and Vaccines
  Infectious Disease Immunotherapies and Vaccines

Chapter 4
EXAMPLES OF CURRENT AND EMERGING APPROACHES TO ENHANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE
4.1. New Approaches for Cancer Immunotherapy and Vaccines
  Nonspecific Active Immunotherapy (Immune-Modulating Agents)
  Antigen Immunotherapies/Vaccines (Allogeneic)
  Autologous Antigen Immunotherapies/Vaccines
  Allogeneic Whole-Tumor-Cell Immunotherapies/Vaccines
  Autologous Whole-Tumor-Cell Immunotherapies/Vaccines
  Dendritic Cell Immunotherapies/Vaccines
  DNA and Viral Vector Vaccines
4.2. Infectious Disease Vaccines
  Types of Vaccines
  Adjuvants

Chapter 5
CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
5.1. Brain Cancer
  Advantagene
  Antisense Pharma
  Celldex Therapeutics
  Merck Serono
  Northwest Biotherapeutics
5.2. Breast Cancer
  Antigen Express (Subsidiary of Generex Biotechnology)
  Apthera
  Celldex Therapeutics
  Introgen Therapeutics
  Peregrine Pharmaceuticals
5.3. Cervical Cancer
5.4. Colorectal Cancer
  Celldex Therapeutics
  GenVec
  immatics biotechnologies
  Oxford BioMedica and sanofi-aventis
  Vaccinogen
5.5. Leukemia
  Argos Therapeutics
  Cell Genesys
  Geron
  The Vaccine Company
5.6. Lung Cancer
  Agennix
  AVAX Technologies
  GlaxoSmithKline
  GlobeImmune
  IDM Pharma
  Introgen Therapeutics
  Merck Serono and Oncothyreon
  Merck Serono
  NovaRx
  Peregrine Pharmaceuticals
  Pfizer
  Pharmexa
  Transgene
  Vaxon Biotech
5.7. Lymphoma (Non–Hodgkin’s Lymphoma)
  Biovest International
  Transgene
5.8. Melanoma
  Antigenics
  AVAX Technologies
  BioVex
  GenVec
  GlaxoSmithKline
  Medarex and Bristol-Myers Squibb
  Merck Serono
  Oxford BioMedica
  Sanofi Pasteur
  SciClone Pharmaceuticals and Sigma-Tau
  Vical
  ZymoGenetics
5.9. Ovarian Cancer
  AVAX Technologies
  Menarini Group
5.10. Pancreatic Cancer
  Celldex Therapeutics
  Cell Genesys
  GenVec
  GlobeImmune
  Lorus Therapeutics and Zor Pharmaceuticals
  Pharmexa
5.11. Prostate Cancer
  Advantagene
  Bavarian Nordic
  Cell Genesys
  Dendreon
  Northwest Biotherapeutics
  Onyvax
  Oxford BioMedica and sanofi-aventis
5.12. Renal Cancer
  Active Biotech
  Agennix
  Antigenics
  Argos Therapeutics
  Endocyte
  Idera Pharmaceuticals and Merck Serono
  immatics biotechnologies
  LipoNova
  Oxford BioMedica and sanofi-aventis
  ZymoGenetics
5.13. Immunotherapies and Vaccines in Development for Other or Nonspecified Cancer Indications

Chapter 6
IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT FOR PREVENTION AND TREATMENT OF INFECTIOUS DISEASES
6.1. Anthrax and Other Biodefense Vaccines
6.2. Campylobacter and/or Enterotoxigenic Escherichia coli (Traveler’s Diarrhea)
  Ace Biosciences
  Intercell
6.3. Cytomegalovirus
  Vical
6.4. Dengue
  GlaxoSmith Kline
  Sanofi Pasteur
6.5. Encephalitis
  Novartis and Intercell
  Sanofi Pasteur
6.6. Hepatitis B
  Emergent BioSolutions
  Merck and Dynavax
6.7. Hepatitis C
  GlobeImmune
  Hemispherx Biopharma
  Human Genome Sciences and Novartis
  Novartis Vaccines and Intercell
  SciClone Pharmaceuticals
6.8. Herpes Simplex Virus
  GlaxoSmithKline
6.9. Human Immunodeficiency Virus (HIV)
  Argos Therapeutics
  Bionor Immuno
  GenVec
  Hemispherx Biopharma
  Sanofi Pasteur
  Targeted Genetics
6.10. Human Papillomavirus (HPV)
  GlaxoSmithKline
  Merck
  MGI Pharma (Subsidiary of Eisai)
  Transgene and Roche
6.11. Influenza
  Baxter Vaccines
  CSL Biotherapies
  GlaxoSmithKline
  Novartis Vaccines
  Protein Sciences Corporation
  Sanofi Pasteur
6.12. Malaria
  GlaxoSmithKline
6.13. Meningococcal Disease; Neisseria meningitidis
  GlaxoSmithKline
  Novartis
6.14. Pneumococcal Disease; Streptococcus pneumoniae
  GlaxoSmithKline
  Wyeth
6.15. Respiratory Syncytial Virus
6.16. Tuberculosis
  Emergent BioSolutions
  GlaxoSmithKline
6.17. West Nile Virus
  Sanofi Pasteur
6.18. Emerging Combination Vaccines
6.19. Other Emerging Infectious Disease Vaccines

Chapter 7
SELECTED BUSINESS CONSIDERATIONS: IMMUNOTHERAPIES AND VACCINES THAT ENHANCE THE IMMUNE SYSTEM
7.1. Companies in the Infectious Disease and Cancer Vaccines and Immunotherapies Fields
7.2. Diseases Targeted for Product Development

  Infectious Disease
  Cancer
7.3. Technical Issues and Challenges for Cancer and Infectious Disease Vaccines and Immunotherapies
7.4. Partners (Corporate and Noncorporate) and Acquisitions
7.5. Human Papillomavirus—Infectious Disease Prophylactic Vaccine for Prevention of Cancer: Example of a Controversy with a New Vaccine

  Social Issues
  Safety Issues

Chapter 8
EXPERT INTERVIEWS
Estuardo Aguilar-Cordova, MD
, Founder & Chief Executive Officer, Advantagene, Inc., Waban, MA
David Apelian, MD, PhD, MBA, Vice President, Clinical Development and Regulatory Affairs, and Chief Medical Officer, GlobeImmune, Louisville, CO
Robert Coffin, PhD, Chief Technology Officer, Founder and Director, BioVex, Woburn, MA
Raafat E.F. Fahim, PhD, President and Chief Executive Officer, Nabi Pharmaceuticals, Rockville, MD
Drew Hannaman, Vice President, Research and Development, Ichor Medical Systems, San Diego, CA
Kristen M. Hege, MD, Vice President, Clinical Research and Development, Cell Genesys, South San Francisco, CA
Frank Malinoski, MD, PhD, Senior Vice President, Medical and Scientific Affairs, MedImmune, Gaithersburg, MD
Cynthia W. Tuthill, PhD, Senior Vice President, Scientific Affairs, & Chief Scientific Officer, SciClone Pharmaceuticals, Foster City, CA
Sunny Uberoi, Vice President, Corporate Communications, Antigenics, New York, NY

References

Company Index with Web Addresses